Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Uninterrupted ibrutinib with CAR T may boost outcomes in CLL

Gauthier J et al. ASH 2018, Abstract 299

Key clinical point: Continuing ibrutinib during CAR T-cell therapy in patients with chronic lymphocytic leukemia appears to improve outcomes and reduce risk of severe cytokine release syndrome.

Major finding: Severe cytokine release syndrome occurred in 0% versus 25% of patients in the ibrutinib and no-ibrutinib cohorts, respectively.

Study details: A retrospective comparison of 43 patients in two cohorts from a phase 1/2 study.

Disclosures: Dr. Gauthier reported having no financial disclosures.

Read the Article.


Gauthier J et al. ASH 2018, Abstract 299